| |
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria.
|
|
Today’s Big NewsAug 13, 2024 |
|
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
| By Nick Paul Taylor Rivus Pharmaceuticals has plumped up the prospects of its fat busting, muscle sparing drug candidate, reporting a primary endpoint hit in a phase 2a trial of people with obesity-related heart failure. |
|
|
|
By Fraiser Kansteiner After seeking to block the launch of MSN Pharmaceuticals’ recently approved Entresto generic, Novartis has hit a snag in its multiyear crusade to thwart copycats of its top-selling heart failure drug. |
By Conor Hale Baxter estimated it will net about $3 billion in cash for the company and its about 23,000 employees, which were once slated to become an independent venture before the end of this year. |
By Fraiser Kansteiner As part of a restructuring initiative, Lexicon Pharmaceuticals will lay off more than 75 staffers, or approximately 50% of its current field force, by the end of September. |
|
September 9-12, 2024 | Philadelphia, PA Join us at Digital Pharma East, the leading event for digital innovation in the pharmaceutical industry. Dive into key topics including Digital Marketing, Data & Analytics, and Patient Engagement. Learn from industry experts, network with peers, and explore cutting-edge strategies to drive your digital initiatives forward. Last Chance – one month left!
|
|
By James Waldron Only five months after securing a $100 million IPO, Boundless Bio is already laying off some employees as the precision oncology company grapples with low enrollment for a trial of its lead drug. |
By Darren Incorvaia Despite maintaining its recent winning streak in the clinic, Acelyrin is no longer focused on its former lead asset izokibep. |
By Fraiser Kansteiner As Novo Nordisk moves full speed ahead on global regulatory filings for a combination of once-weekly insulin icodec and semaglutide, the U.S. won’t be part of that plan for the time being, thanks to a recent regulatory hiccup with the FDA. |
By Nick Paul Taylor The National Advertising Division (NAD) has sided with Johnson & Johnson Consumer Inc (JJCI) in a row over ads for wound dressings, recommending ASO drop its “2x faster healing” claims for its hydrocolloid bandages. |
By Nick Paul Taylor Eli Lilly has opened a $700 million R&D center in the Boston Seaport, boosting its RNA and DNA research capabilities and expanding its biotech-hosting Gateway Labs to the East Coast for the first time. |
By Conor Hale The Biden administration will deliver $150 million in cancer moonshot funds to new tech that aims to make tumor surgeries safer and more precise. |
By Angus Liu A deal to bring back former CEO Robert Foster, Ph.D., didn’t completely quell investors’ concerns about Aurinia Pharmaceuticals. |
By James Waldron “Following Takeda's unexpected phase 3 results for soticlestat, we moved rapidly to focus our resources to preserve capital,” Ovid CEO Jeremy Levin said. |
By Conor Hale Absci has joined up with Memorial Sloan Kettering Cancer Center on a project to co-develop as many as six potential antibody therapies. |
By Andrea Park Amid ongoing debates over whether direct-to-consumer pharmaceutical advertisements should be banned in the U.S., as they are in almost every other country, a new study suggests that many doctors and patients actually find the ad spots to be more helpful than harmful. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. |
|
|---|
|
|
|
Thursday, September 12, 2024 | 10am ET / 7am PT Nitrosamines, potent carcinogens, have prompted stringent regulations for their detection and control in various products. With regulatory bodies demanding robust analytical methods and risk assessments, pharmaceutical and medical devices manufacturers must stay on top of the current regulatory landscape and compliance strategies. Register now for access to the key insights you need to know. |
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
